Actavis' Generic Lialda Still Too Early, Judge Finds

Law360, New York (March 28, 2016, 5:23 PM EDT) -- A Florida federal judge on Monday barred Actavis from launching its generic version of Shire's inflammatory bowel disease treatment Lialda until the patent for the drug expires in June 2020, following a second bench trial on the matter.

U.S. District Judge Donald M. Middlebrooks found that Actavis Inc. infringed the patent for Lialda, which he said was valid, when the company applied for regulatory approval of a generic version of the drug, mirroring his 2013 decision in the first bench trial. The judge said Actavis' generic version still infringed the patent after applying the additional standards the Federal Circuit set in its...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!